Edgar Faber

2.3k total citations
85 papers, 814 citations indexed

About

Edgar Faber is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Edgar Faber has authored 85 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hematology, 43 papers in Genetics and 23 papers in Rheumatology. Recurrent topics in Edgar Faber's work include Chronic Lymphocytic Leukemia Research (42 papers), Chronic Myeloid Leukemia Treatments (42 papers) and Eosinophilic Disorders and Syndromes (23 papers). Edgar Faber is often cited by papers focused on Chronic Lymphocytic Leukemia Research (42 papers), Chronic Myeloid Leukemia Treatments (42 papers) and Eosinophilic Disorders and Syndromes (23 papers). Edgar Faber collaborates with scholars based in Czechia, Finland and United States. Edgar Faber's co-authors include Karel Indrák, David Friedecký, Tomáš Adam, Luděk Raida, Marie Jarošová, Richard Pink, J Pazdera, Tomáš Papajík, J Šimek and Peter Rohoň and has published in prestigious journals such as Blood, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Edgar Faber

75 papers receiving 782 citations

Peers

Countries citing papers authored by Edgar Faber

Since Specialization

Citations

This map shows the geographic impact of Edgar Faber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edgar Faber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edgar Faber more than expected).

Fields of papers citing papers by Edgar Faber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edgar Faber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edgar Faber. The network helps show where Edgar Faber may publish in the future.

Co-authorship network of co-authors of Edgar Faber

This figure shows the co-authorship network connecting the top 25 collaborators of Edgar Faber. A scholar is included among the top collaborators of Edgar Faber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edgar Faber. Edgar Faber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data 2024 ·Cancer Medicine ·(unknown), Daniela Žáčková, Hana Klamová, Edgar Faber, Michal Karas, (unknown), (unknown), O Cerná, (unknown), Kateřina Machová Poláková, Павел Зак, (unknown), (unknown), Jiřı́ Mayer	0
2	Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia 2023 ·International Journal of Molecular Sciences ·(unknown), Vladimír Divoký, (unknown), Kateřina Machová Poláková, Eva Kriegová, (unknown), (unknown), (unknown), Tomáš Papajík, Edgar Faber	0
3	Elevated erythroferrone distinguishes erythrocytosis with inherited defects in oxygen‐sensing pathway from primary familial and congenital polycythaemia 2023 ·British Journal of Haematology ·(unknown), (unknown), Jana Kučerová, Dagmar Pospı́šilová, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Eva Kriegová, Karel Indrák, Edgar Faber, Vladimír Divoký, Monika Horváthová	3
4	Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site 2022 ·Biomedical Papers ·Martin Čerňan, Tomáš Szotkowski, (unknown), Milan Kolář, Edgar Faber, Karel Indrák, Tomáš Papajík	1
5	NFKB1 gene single-nucleotide polymorphisms: implications for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation 2020 ·Annals of Hematology ·(unknown), Luděk Raida, František Mrázek, (unknown), Eva Kriegová, Kateřina Langová, Tomáš Fürst, Jana Fürstová, Edgar Faber, Tomáš Papajík	5
6	Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience 2018 ·Transfusion Clinique et Biologique ·(unknown), (unknown), (unknown), Luděk Raida, Tomáš Szotkowski, (unknown), Peter Rohoň, (unknown), Karel Indrák, Tomáš Papajík, Milan Kolář, Edgar Faber	0
7	Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis 2017 ·European Journal of Pharmaceutical Sciences ·Ivo Vrobel, David Friedecký, Edgar Faber, Lukáš Najdekr, (unknown), Radana Brumarová, Tomáš Adam	8
8	Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients 2016 ·PLoS ONE ·(unknown), Peter Rohoň, Hana Klamová, O Cerná, (unknown), (unknown), (unknown), (unknown), Iuri Marinov, Simona Soverini, Edgar Faber, Kateřina Machová Poláková	16
9	A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment 2015 ·Leukemia & lymphoma ·Edgar Faber, (unknown), (unknown), (unknown), (unknown), (unknown), David Friedecký, Tomáš Adam, Marie Jarošová, Karel Indrák	21
10	Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma 2012 ·Talanta ·(unknown), David Friedecký, Edgar Faber, Tomáš Adam	23
11	High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma 2012 ·Leukemia & lymphoma ·Vít Procházka, Edgar Faber, Luděk Raida, Kateřina Langová, Karel Indrák, Tomáš Papajík	12
12	Operational Cures After Interferon-Alpha in Patients with Chronic Myeloid Leukemia in Central and Northern Moravia 2011 ·Journal of Interferon & Cytokine Research ·Edgar Faber, (unknown), Jana Zapletalová, (unknown), (unknown), Peter Rohoň, (unknown), Marie Jarošová, (unknown)	1
13	Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response 2010 ·International Journal of Hematology ·Edgar Faber, David Friedecký, (unknown), (unknown), (unknown), (unknown), Marie Jarošová, Karel Indrák, Tomáš Adam	10
14	Precursor T-Lymphoblastic Lymphoma as a Secondary Malignancy in a Young Patient after Successful Treatment of Acute Promyelocytic Leukemia 2009 ·Onkologie ·Tomáš Szotkowski, Marie Jarošová, Edgar Faber, (unknown), (unknown), Tomáš Papajík, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Karel Indrák	4
15	Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation 2009 ·Bone Marrow Transplantation ·(unknown), František Mrázek, Luděk Raida, Peter Jindra, Blanka Vidan‐Jeras, Edgar Faber, Janja Pretnar Oblak, Karel Indrák, Martin Petřek	38
16	PROLONGED SURVIVAL OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA AFTER FIRST-LINE INTENSIVE SEQUENTIAL CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION 2009 ·Biomedical Papers ·Vít Procházka, Edgar Faber, Luděk Raida, (unknown), (unknown), Marie Jarošová, Karel Indrák, Tomáš Papajík	9
17	Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation 2009 ·Human Immunology ·(unknown), František Mrázek, Luděk Raida, (unknown), Edgar Faber, Karel Indrák, Martin Petřek	9
18	SUCCESSFUL CHILDBIRTH IN A PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH IMATINIB MESYLATE DURING EARLY PREGNANCY 2008 ·Biomedical Papers ·(unknown), (unknown), Peter Rohoň, (unknown), Marie Jarošová, Karel Indrák, Martin Procházka, (unknown), Edgar Faber	10
19	SOURCES AND PATHWAYS OF SPREAD OF VANCOMYCIN-RESISTANT ENTEROCOCCI IN HEMATO-ONCOLOGICAL PATIENTS 2006 ·Biomedical Papers ·(unknown), Pavel Šauer, Milan Kolář, (unknown), (unknown), Edgar Faber, Luděk Raida, Tomáš Papajík	3
20	Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients 2003 ·The Hematology Journal ·(unknown), Jaroslav Bačovský, Karel Indrák, (unknown), (unknown), Edgar Faber, Tomáš Papajík, Zdeněk Adam, Roman Hájek, Pavel Hořák, Arnošt Martínek	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact